✦ LIBER ✦

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

✍ Scribed by R Ling; D Mutimer; M Ahmed; E H Boxall; E Elias; G M Dusheiko; T J Harrison

Publisher: John Wiley and Sons
Year: 1996
Tongue: English
Weight: 180 KB
Volume: 24
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.510240339

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevalence and profile of mutations asso

Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus

✍ Salma M. Wakil; Syed N. Kazim; Luqman A. Khan; Sheikh Raisuddin; Mohammad K. Par 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 1 views

## Abstract Lamivudine results in the selection of resistant hepatitis B virus (HBV) variants. Because the surface gene of HBV overlaps completely the polymerase gene, the incidence and profile of surface and polymerase gene mutations were investigated prospectively in chronic HBV patients who were

Novel patterns of amino acid mutations i

Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B

✍ Ogata, Norio; Fujii, Kyuichi; Takigawa, Shingo; Nomoto, Minoru; Ichida, Takafumi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 2 views

Lamivudine is effective in suppressing replication of hepatitis B virus (HBV). However, the emergence of HBV variants resistant to lamivudine is a concern. Lamivudine resistance has been attributed mainly to a substitution of isoleucine or valine for methionine at residue 550 (M550I or M550V) in the

Evolution of hepatitis B virus sequence

Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy

✍ Kyun-Hwan Kim; Kwang-Hee Lee; Hye-Young Chang; Sang Hoon Ahn; Shuping Tong; Youn 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

## Abstract Recurrent hepatitis B virus (HBV) infection after liver transplantation can be prevented by prophylactic hepatitis B immune globulin (HBIG) and lamivudine therapy. However, reinfection may still occur due to the emergence of immune escape mutants and mutants of the YMDD motif. The full

Mutational pattern of hepatitis B virus

Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantation

✍ Hans L. Tillmann; Christian Trautwein; Thomas Bock; Klaus H. Böker; Elmar Jäckel 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 1 views

## Famciclovir (FCV) and lamivudine (LAM) reduce viral replication in patients with recurrent hepatitis B virus (HBV) infection after orthotopic liver transplantation (OLT). Eighteen of 20 patients with insufficient response to FCV were treated with 100 mg LAM daily after OLT. These patients had s

Acute exacerbation and hepatitis B virus

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

✍ Yun-Fan Liaw; Rong-Nan Chien; Chau-Ting Yeh; Sun-Lung Tsai; Chia-Ming Chu 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB 👁 1 views

Lamivudine is a potent inhibitor of hepatitis B virus (HBV) replication, but its long-term use may be associated with HBV tyrosine-methionine-aspartate-aspartate (YMDD) motif mutation. To examine the clinical features and course after emergence of YMDD mutants, 55 patients who received lamivudine th

Lamivudine in the treatment of hepatitis

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

✍ Yeo, Winnie; Steinberg, Joyce L.; Tam, John S.; Chan, Paul K.S.; Leung, Nancy W. 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

Hepatitis B virus (HBV) reactivation has been described in cancer patients who received cytotoxic/immunosuppressive therapy and may result in liver damage of varying degrees of severity. There is no known effective treatment. Lamivudine, a nucleoside analogue, has been found to suppress HBV replicat